Neurocrine Begins Phase 2 Trial for MDD Drug NBI-1070770

Neurocrine Biosciences, a biopharmaceutical firm specializing in neuroscience, has initiated a Phase 2 clinical trial for a new drug candidate, NBI-1070770, which is designed to treat adults suffering from major depressive disorder (MDD). The compound is a selective negative allosteric modulator (NAM) that targets the NR2B subunit of the N-methyl-D-aspartate (NMDA) receptor, offering a novel oral treatment option for MDD patients.
Eiry W. Roberts, the company's Chief Medical Officer, expressed enthusiasm for the clinical development of NBI-1070770, highlighting its potential to assist patients with moderate to severe depression. The Phase 2 study, which is a multi-center, randomized, double-blind, and placebo-controlled trial, aims to enroll around 72 adults across various centers in the United States. The primary objective is to assess the drug's safety and efficacy in alleviating depressive symptoms, as measured by the Montgomery-Åsberg Depression Rating Scale.
Neurocrine Biosciences obtained the rights to develop and market NBI-1070770 from Takeda Pharmaceutical Company, Ltd. The company has a track record of over three decades in neuroscience, focusing on neurological, neuroendocrine, and neuropsychiatric disorders. Their portfolio encompasses FDA-approved treatments for conditions like tardive dyskinesia and chorea associated with Huntington's disease, as well as endometriosis and uterine fibroids in collaboration with AbbVie. The company is also engaged in the development of a pipeline of compounds in various stages of clinical trials.
Neurocrine Biosciences is committed to advancing treatments that can significantly improve the lives of patients with complex and debilitating conditions. Their mission is driven by the belief that everyone deserves access to innovative and effective treatments.